Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, Tolerability, PK and PD Study of AD-214 Administered to Healthy Volunteers and Patients With Interstitial Lung Disease or Chronic Kidney Disease

Next Previous
Trial Profile

Safety, Tolerability, PK and PD Study of AD-214 Administered to Healthy Volunteers and Patients With Interstitial Lung Disease or Chronic Kidney Disease

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AD-214 (Primary)
  • Indications Fibrosis; Idiopathic pulmonary fibrosis
  • Focus Adverse reactions

Most Recent Events

  • 06 Nov 2023 According to an AdAlta media release, the company has raised dollar 1.65 million in an oversubscribed placement to institutional and sophisticated investors. The raise, for which the company was initially targeting $1.23 million, was strongly supported by major shareholders and a life sciences-focused institutional investor. The net proceeds will be used to complete the final analysis of the healthy volunteer cohort.
  • 21 Sep 2023 According to an AdAlta media release, eight participants have successfully received at least their first dose of AD-214 or a placebo.
  • 21 Sep 2023 According to an AdAlta media release, Pharmacokinetic and receptor engagement data are expected by November 2023, while complete safety and tolerability results are slated for release in the first quarter of 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top